The potassium channel KCa3.1 as New therapeutic target for the prevention of obliterative airway disease

Transplantation

Volumn 95, Issue 2, 2013, Pages 285-292

  Hua, Xiaoqin ^a   Deuse, Tobias ^a   Chen, Yi Je ^b   Wulff, Heike ^b   Stubbendorff, Mandy ^a   Köhler, Ralf ^c,d   Miura, Hiroto ^e   Länger, Florian ^f   Reichenspurner, Hermann ^a   Robbins, Robert C ^a   Schrepfer, Sonja ^a  

^a UNIVERSITY HEART CENTER HAMBURG   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^e UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^f HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Chronic rejection; Heterotopic tracheal transplantation.; KCa3.1; Obliterative airway disease; TRAM 34

Indexed keywords

1 [(2 CHLOROPHENYL)DIPHENYLMETHYL] 1H PYRAZOLE; MESSENGER RNA; POTASSIUM CHANNEL KCA3.1; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL;

AIRWAY OBSTRUCTION; ALLOIMMUNITY; ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; ENZYME LINKED IMMUNOSPOT ASSAY; GRAFT PRESERVATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG TRANSPLANTATION; LYMPHOCYTIC INFILTRATION; MALE; NONHUMAN; OBSTRUCTIVE AIRWAY DISEASE; PATHOGENESIS; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TOXICITY TESTING; TRACHEA SURGERY; TREATMENT OUTCOME;

ANIMALS; BRONCHIOLITIS OBLITERANS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSPOT ASSAY; GENETIC THERAPY; INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; ISOANTIBODIES; LYMPHOCYTE ACTIVATION; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, KNOCKOUT; POTASSIUM CHANNEL BLOCKERS; PYRAZOLES; RESPIRATORY MUCOSA; TH1 CELLS; TH2 CELLS; TIME FACTORS; TRACHEA;

EID: 84872947776     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318275a2f4     Document Type: Article

References (58)

1. Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: twentyseventh official adult lung and heart-lung transplant reportV2010. J Heart Lung Transplant 2010; 29: 1104.
2. Sundaresan S, Trulock EP, Mohanakumar T, et al. Prevalence and outcome of bronchiolitis obliterans syndrome after lung transplantation. Ann Thoracic Surg 1995; 60: 1341.
3. Paradis I, Yousem S, Griffith B. Airway obstruction and bronchiolitis obliterans after lung transplantation. Clin Chest Med 1993; 14: 751.
4. Burke C, Baldwin J, Morris A, et al. Twenty-eight cases of human heart-lung transplantation. Lancet 1986; 327: 517.
5. Griffith BP, Paradis IL, Zeevi A, et al. Immunologically mediated disease of the airways after pulmonary transplantation. Ann Surg 1988; 208: 371.
6. Boehler AKS, Weder W, Speich R. Bronchiolitis obliterans after lung transplantation: a review. Chest 1998; 114: 1411.
7. Adams BF, Brazelton T, Berry GJ, et al. The role of respiratory epithelium in a rat model of obliterative airway disease. Transplantation 2000; 69: 661.
8. George Chandy K, Wulff H, Beeton C, et al. K+ channels as targets for specific immunomodulation. Trends Pharmacol Sci 2004; 25: 280.
9. Gutman GA, Chandy KG, Adelman JP, et al. International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. Pharmacol Rev 2003; 55: 583.
10. Wulff H, Gutman GA, Cahalan MD, et al. Delineation of the clotrimazole/TRAM-34 binding site on the intermediate conductance calcium-activated potassium channel, IKCa1. J Biol Chem 2001; 276: 32040.
11. Cahalan MD, Chandy KG. The functional network of ion channels in T lymphocytes. Immunol Rev 2009; 231: 59.
12. Rus H, Pardo CA, Hu L, et al. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A 2005; 102: 11094.
13. Fanger CM, Rauer H, Neben AL, et al. Calcium-activated potassium channels sustain calcium signaling in T lymphocytes. Selective blockers and manipulated channel expression levels. J Biol Chem 2001; 276: 12249.
14. Ghanshani S, Wulff H, Miller MJ, et al. Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences. J Biol Chem 2000; 275: 37137.
15. Khanna R, Chang MC, Joiner WJ, et al. hSK4/hIK1, a calmodulinbinding KCa channel in human T lymphocytes. J Biol Chem 1999; 274: 14838.
16. Jensen BS, Hertz M, Christophersen P, et al. The Ca2+-activated K+ channel of intermediate conductance:a possible target for immune suppression. Expert Opin Ther Targets 2002; 6: 623.
17. Chou CC, Lunn CA, Murgolo NJ. KCa3.1: target and marker for cancer, autoimmune disorder and vascular inflammation? Expert Rev Mol Diagn 2008; 8: 179.
18. Kohler R, Wulff H, Eichler I, et al. Blockade of the intermediateconductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation 2003; 108: 1119.
19. Tharp DL, Wamhoff BR, Wulff H, et al. Local delivery of the KCa3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis. Arterioscler Thromb Vasc Biol 2008; 28: 1084.
20. Toyama K, Wulff H, Chandy KG, et al. The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. J Clin Invest 2008; 118: 3025.
21. Grgic I, Kiss E, Kaistha BP, et al. Renal fibrosis is attenuated by targeted disruption of K(Ca)3.1 potassium channels. Proc Natl Acad Sci U S A 2009; 106: 14518.
22. Wulff H, Knaus HG, Pennington M, et al. K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity. J Immunol 2004; 173: 776.
23. Wulff H, Calabresi PA, Allie R, et al. The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS. J Clin Invest 2003; 111: 1703.
24. Reznik SI, Jaramillo A, SivaSai KSR, et al. Indirect allorecognition of mismatched donor HLA class II peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Am J Transplant 2001; 1: 228.
25. Lu KC, Jaramillo AS, Mendeloff EN, et al. Concomitant allorecognition of mismatched donor HLA class I- and class II-derived peptides in pediatric lung transplant recipients with bronchiolitis obliterans syndrome. J Heart Lung Transplant 2003; 22: 35.
26. Sundaresan S, Mohanakumar T, Smith MA, et al. HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome. Transplantation 1998; 65: 648.
27. Sekine Y, Yasufuku K, Heidler KM, et al. Monocyte chemoattractant protein-1 and RANTES are chemotactic for graft infiltrating lymphocytes during acute lung allograft rejection. Am J Respir Cell Mol Biol 2000; 23: 719.
28. Schmid-Antomarchi H, Schmid-Alliana A, Romey G, et al. Extracellular ATP and UTP control the generation of reactive oxygen intermediates in human macrophages through the opening of a charybdotoxinsensitive Ca2+-dependent K+ channel. J Immunol 1997; 159: 6209.
29. Hertz MI, Henke CA, Nakhleh RE, et al. Obliterative bronchiolitis after lung transplantationVa fibroproliferative disorder associated with platelet-derived growth factor. Proc Natl Acad Sci U S A 1992; 89: 10385.
30. Oyaizu T, Okada Y, Shoji W, et al. Reduction of recipient macrophages by gadolinium chloride prevents development of obliterative airway disease in a rat model of heterotopic tracheal transplantation. Transplantation 2003; 76: 1214.
31. Smith CR, Jaramillo AS, Duffy BF, et al. Airway epithelial cell damage mediated by antigen-specific T cells: implications in lung allograft rejection. Hum Immunol 2000; 61: 985.
32. Nakajima J, Ono M, Takeda M, et al. Role of costimulatory molecules on airway epithelial cells acting as alloantigen-presenting cells. Transpl Proc 1997; 29: 2297.
33. Di L, Srivastava S, Zhdanova O, et al. Inhibition of the K(+) channel KCa3.1 ameliorates T cell-mediated colitis. Proc Natl Acad Sci U S A 2010; 107: 1541.
34. Lau CL, Palmer SM, Posther KE, et al. Influence of panel-reactive antibodies on posttransplant outcomes in lung transplant recipients. Ann Thorac Surg 2000; 69: 1520.
35. Mauck KA, Hosenpud JD. The bronchial epithelium: a potential allogeneic target for chronic rejection after lung transplantation. J Heart Lung Transplant 1996; 15: 709.
36. Kuo E, Bharat A, Shih J, et al. Role of airway epithelial injury in murine orthotopic tracheal allograft rejection. Ann Thorac Surg 2006; 82: 1226.
37. Qu N, de Vos P, Schelfhorst M, et al. Integrity of airway epithelium is essential against obliterative airway disease in transplanted rat tracheas. J Heart Lung Transplant 2005; 24: 882.
38. Ikonen TS, Brazelton TR, Berry GJ, et al. Epithelial re-growth is associated with inhibition of obliterative airway disease in orthotopic tracheal allografts in non-immunosuppressed rats. Transplantation 2000; 70: 857.
39. Deuse T, Schrepfer S, Reichenspurner H, et al. Techniques for experimental heterotopic and orthotopic tracheal transplantationsV when to use which model? Transpl Immunol 2007; 17: 255.
40. Chen YJ, Raman G, Bodendiek S, et al. The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/ reperfusion stroke. J Cereb Blood Flow Metab 2011; 31: 2363.
41. Hu L, Mullen K, Allie R, et al. Blockade of Kv1.3 potassium channels inhibits granzyme B production in human CD8+ T lymphocytes. Clin Immunol 2006; 119: S45.
42. Ataga KI, Orringer EP, Styles L, et al. Dose-escalation study of ICA- 17043 in patients with sickle cell disease. Pharmacotherapy 2006; 26: 1557.
43. Ataga KI, Smith WR, De Castro LM, et al. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood 2008; 111: 3991.
44. Wulff H, Castle NA. Therapeutic potential of KCa3.1 blockers: recent advances and promising trends. Expert Rev Clin Pharmacol 2010; 3: 385.
45. Todd JL, Palmer SM. Bronchiolitis obliterans syndrome: the final frontier for lung transplantation. Chest 2011; 140: 502.
46. Jaramillo A, Ferna'ndez FG, Kuo EY, et al. Immune mechanisms in the pathogenesis of bronchiolitis obliterans syndrome after lung transplantation. Pediatr Transplant 2005; 9: 84.
47. Burke CM, Theodore J, Dawkins KD, et al. Post-transplant obliterative bronchiolitis and other late sequelae in human heart-lung transplantation. Chest 1984; 86: 824.
48. Cairn J, Yek T, Banner NR, et al. Time-related changes in pulmonary function after conversion to tacrolimus in bronchiolitis obliterans syndrome. J Heart Lung Transplant 2003; 22: 50.
49. Groetzner J, Wittwer T, Kaczmarek I, et al. Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation. Transplantation 2006; 81: 355.
50. Gottlieb J, Szangolies J, Koehnlein T, et al. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2008; 85: 36.
51. Johnson BA, Iacono AT, Zeevi A, et al. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med 2003; 167: 1271.
52. Morrell MR, Despotis GJ, Lublin DM, et al. The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2010; 29: 424.
53. Si H, Heyken W-T, Wo?lfle SE, et al. Impaired endothelium-derived hyperpolarizing factor-mediated dilations and increased blood pressure in mice deficient of the intermediate-conductance Ca2+-activated K+ channel. Circ Res 2006; 99: 537.
54. Hele DJ YM, Belvisi MG. The heterotopic tracheal allograft as an animal model of obliterative bronchiolitis. Respir Res 2001; 2: 169.
55. Hua X, Deuse T, Tang-Quan KR, et al. Heterotopic and orthotopic tracheal transplantation in mice used as models to study the development of obliterative airway disease. J Vis Exp 2010; 35: 1437.
56. Wulff H, Miller MJ, Hansel W, et al. Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant. Proc Natl Acad Sci U S A 2000; 97: 8151.
57. Reichenspurner H, Soni V, Nitschke M, et al. Obliterative airway disease after heterotopic tracheal xenotransplantation: pathogenesis and prevention using new immunosuppressive agents. Transplantation 1997; 64: 373.
58. Velotta JB, Deuse T, Peter C, et al. Effects of the JAK3-inhibitor R348 on different cell types involved in obliterative airway disease. J Heart Lung Transplant 2009; 28: S180.